Cellular and Humoral Immunity to SARS‐CoV‐2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease‐Modifying Therapies: A Multi‐Ethnic Observational Study

Article activity feed

1. Version published to 10.1002/ana.26346

   Apr 1, 2022
2. 

   ScreenIT

   Jan 12, 2022

   SciScore for 10.1101/2022.01.10.22268752: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Ethics	not detected.
   Sex as a biological variable	not detected.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   Values ≥1.0 U/mL were interpreted as ‘positive’ for anti-N SARS-CoV-2 antibodies.	anti-N SARS-CoV-2 suggested: None
   The levels of antibodies were expressed in U/mL, which are considered equivalent to Binding Antibody Units (BAU)/mL (Elecsys S Units = 0.972 x BAU), as defined by the first World Health Organization (WHO) International Standard for anti-SARS-CoV-2 immunoglobulin (NIBSC code 20/136).32 2.	anti-SARS-CoV-2 immunoglobulin suggested: None
   NYU proprietary custom Multiepitope …

   SciScore for 10.1101/2022.01.10.22268752: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Ethics	not detected.
   Sex as a biological variable	not detected.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   Values ≥1.0 U/mL were interpreted as ‘positive’ for anti-N SARS-CoV-2 antibodies.	anti-N SARS-CoV-2 suggested: None
   The levels of antibodies were expressed in U/mL, which are considered equivalent to Binding Antibody Units (BAU)/mL (Elecsys S Units = 0.972 x BAU), as defined by the first World Health Organization (WHO) International Standard for anti-SARS-CoV-2 immunoglobulin (NIBSC code 20/136).32 2.	anti-SARS-CoV-2 immunoglobulin suggested: None
   NYU proprietary custom Multiepitope Bead-based Immunoassay (MBI), which measures antibody responses to three recombinant proteins (Wuhan variant total Spike, RBD and the S amino-terminal domain (NTD); Sino Biological cat no. 40590-V08B, 40592-V08B, 40591-V49H-B, respectively), using control analytes of Human serum albumin (HSA), tetanus toxoid and anti-human IgG (Jackson Immunoresearch Inc.) coupled to commercial paramagnetic beads (MagPix, Luminex), as adapted from the manufacturer’s instructions as previously described.	anti-human IgG suggested: None
   Experimental Models: Cell Lines
   Sentences	Resources
   SARS-CoV-2 viral neutralization activity of plasma was measured in an immunofluorescence-based assay that detects the neutralization of infectious virus (SARS-CoV-2 isolate USA-WA1/2020 (NR-52281, GenBank accession no. MT233526) in cultured Vero E6 cells (African Green Monkey Kidney; ATCC #CRL-1586) as described in detail in 35.	Vero E6 suggested: None

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

   Limitations of our study include the lack of SARS-CoV-2 PCR confirmation for all of our patients, especially those infected during the first wave, in which 80% of patients were not PCR-confirmed.55 Our inclusion criteria, though intentionally broad, precluded older, systemically immunocompromised, severely disabled patients from participation. Patients who were lost due to fatal COVID-19 infection could not be accounted for in our study. Our patients largely reflect the mild range within the spectrum of SARS-CoV-2, as evidenced by the fact that only 7% of our symptomatic cases were hospitalized as compared to the average hospitalization rate of 16% across MS studies 56. Our findings may not be generalizable to older and more disabled patients, who account for the bulk of excess morbidity and mortality in MS.57 The main conclusion of our study is that relatively young and otherwise healthy MS patients generally had favorable clinical course across DMTs despite markedly impaired adaptive immune responses associated with some of the DMTs (aCD20, S1P). To better understand the uncoupling of T-cell from antibody responses in aCD20 treated patients and to identify predictors of immune response in patients on the different DMTs, we are conducting in-depth immunophenotyping and activation-induced marker studies. Race/ethnicity did not predict either clinical or immunologic outcomes.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Results from scite Reference Check: We found no unreliable references.

   ---

   Read the original source
3. 

   Version published to 10.1101/2022.01.10.22268752v1 on medRxiv

   Jan 10, 2022